Deferasirox

Deferasirox

SCHEMBL61756

O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 3/20 1.00
KDM6B O15054 1/20 1.00
ABCC4 O15439 1/20 1.00
ABCB11 O95342 1/20 1.00
KDM5A P29375 1/20 1.00
BLVRB P30043 1/20 1.00
SCN5A Q14524 1/20 1.00
KCND3 Q9UK17 1/20 1.00
KEAP1 Q14145 1/20 0.55
LMNA P02545 2/20 0.52
TSHR P16473 1/20 0.52
USP2 O75604 1/20 0.50
ALDH1A1 P00352 1/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
HPGD P15428 1/20 0.50
KMT2A Q03164 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Deferasirox SCHEMBL29381781 1.00 KDM4A (1.00) KDM4AKDM6BABCC4ABCB11KDM5A
SCHEMBL5843740 0.92 KDM4A (0.85) KDM4AKDM6BABCC4ABCB11KDM5A
SCHEMBL20080980 0.92 KDM4A (0.85) KDM4AKDM6BABCC4ABCB11KDM5A
SCHEMBL5843247 0.90 KDM4A (0.81) KDM4AKDM6BABCC4ABCB11KDM5A
SCHEMBL5842285 0.90 KDM4A (0.81) KDM4AKDM6BABCC4ABCB11KDM5A
SCHEMBL22184113 0.89 KDM4A (0.80) KDM4AKDM6BABCC4ABCB11KDM5A
SCHEMBL20620461 0.89 KDM4A (0.80) KDM4AKDM6BABCC4ABCB11KDM5A
SCHEMBL25697702 0.89 KDM4A (0.80) KDM4AKDM6BABCC4ABCB11KDM5A
SCHEMBL4370368 0.88 KDM4A (1.00) KDM4AKDM6BABCC4ABCB11KDM5A
SCHEMBL19722958 0.88 KDM4A (0.78) KDM4AKDM6BABCC4ABCB11KDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1998 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739300-A1 MODULATORS OF IRON METABOLISM FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION SORBONNE UNIVERSITE (FR) 2026-05-13 EP claimed
EP-3310354-B1 IMPROVED FORMULATIONS OF DEFERASIROX AND METHODS OF MAKING THE SAME AUSTINPX LLC (US) 2026-02-25 EP claimed
US-12544406-B2 Induced pluripotent stem cell derived glial enriched progenitor cells for the treatment of white matter stroke THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-02-10 US claimed
US-20250388791-A1 CYCLIC ACETAL CROSSLINKER AND SOLVENT FOR FORMALDEHYDE RESIN HEXION INC. (US) 2025-12-25 US claimed
US-20250275946-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER UNM RAINFOREST INNOVATIONS (US) 2025-09-04 US claimed
US-20250221415-A1 Materials and Methods for Treating Iron Deficiencies and Iron Chlorosis in Plants LOCUS SOLUTIONS IPCO, LLC 2025-07-10 US claimed
US-20250194641-A1 Materials and Methods for Iron Capture and Greenhouse Gas Reduction LOCUS SOLUTIONS IPCO, LLC 2025-06-19 US claimed
US-20250187058-A1 Materials and Methods for Remediating and Mitigating Iron Pollution LOCUS SOLUTIONS IPCO, LLC 2025-06-12 US claimed
US-20250176557-A1 Materials and Methods for Control of Iron-Capturing Pathogens LOCUS SOLUTIONS IPCO, LLC 2025-06-05 US claimed
EP-4551341-A1 MATERIALS AND METHODS FOR REMEDIATING AND MITIGATING IRON POLLUTION Locus Solutions IPCO, LLC (US) 2025-05-14 EP claimed
WO-2005058320-A1 COMBINATION OF (a) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF NOVARTIS AG (CH) 2005-06-30 WO claimed
JP-3541042-B2 2004-07-07 JP claimed
US-20030203954-A1 Substituted 3, 5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators LATTMANN RENE (CH) 2003-10-30 US claimed
US-6596750-B2 Compounds have useful pharmaceutical properties and are particularly active as iron chelators. They can be used for the treatment of iron overload in warm-blooded animals. NOVARTIS AG (CH) 2003-07-22 US claimed
US-20030069273-A1 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators LATTMANN RENE (CH) 2003-04-10 US claimed
EP-0914118-B1 SUBSTITUTED 3,5-DIPHENYL-1,2,4-TRIAZOLES AND THEIR USE AS PHARMACEUTICAL METAL CHELATORS NOVARTIS AG (CH) 2002-10-23 EP claimed
US-6465504-B1 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators NOVARTIS AG (CH) 2002-10-15 US claimed
JP-2000507601-A 2000-06-20 JP claimed
EP-0914118-A1 SUBSTITUTED 3,5-DIPHENYL-1,2,4-TRIAZOLES AND THEIR USE AS PHARMACEUTICAL METAL CHELATORS Novartis AG (CH) 1999-05-12 EP claimed
WO-1997049395-A1 SUBSTITUTED 3,5-DIPHENYL-1,2,4-TRIAZOLES AND THEIR USE AS PHARMACEUTICAL METAL CHELATORS NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. (AT) 1997-12-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069273-A1 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators TFRC, SLC40A1, FECH KDM4A 2799/4885KDM6B 2804/4885ABCC4 679/4885
US-12544406-B2 Induced pluripotent stem cell derived glial enriched progenitor cells for the treatment of white matter stroke GFRA3, NES, DCX KDM4A 2939/4885KDM6B 1823/4885ABCC4 1755/4885
US-20250388791-A1 CYCLIC ACETAL CROSSLINKER AND SOLVENT FOR FORMALDEHYDE RESIN SMCHD1, FGB, UFL1 KDM4A 304/4885KDM6B 287/4885ABCC4 2471/4885
US-20030203954-A1 Substituted 3, 5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators TFRC, SLC40A1, FECH KDM4A 2799/4885KDM6B 2804/4885ABCC4 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.